acute myeloid leukemia

[SELLAS Life Sciences Group, Inc.] SELLAS Life Sciences Group, Inc. announced that the first acute myeloid leukemia patient has enrolled in the fifth dose level cohort, out of the expected six dose cohorts, in the ongoing Phase I dose-escalating clinical trial with SELLAS’ newly in-licensed GFH009 asset.

[Acta Biomaterialia] Researchers compared the anti-leukemic ability of pure ABT-199 and PEG-ABT-199 in vitro and in vivo.

[Cell Death Discovery] Researchers showed that hydroxyurea could kill mixed-lineage leukemia-r acute myeloid leukemia cells through the necroptosis process.

[International Journal of Hematology] Scientists investigated the optimal timing and cutoff value to ascertain the value of NPM1 mutation in measurable residual disease assessment.

[Journal of Cancer Research and Clinical Oncology] Nox4 inactivation in normal HSCs and progenitor cells caused a minor reduction in HSC numbers and reconstitution capacity.

[Experimental Cell Research] The authors found that lipid transport-associated genes were upregulated in the high interleukin-6 (IL-6) receptor expression group. IL-6 promoted fatty acid uptake in both AML cell lines and primary AML cells.